

Downloaded from <http://ajph.org/> on November 10, 2014

```

; COUNTRY: USA
; ZIP: 02109
; COMPUTER FEASIBLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC DOS/MS DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/389,459A
; FILING DATE: 15 FEB 1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/087,003
; FILING DATE: 01-JUL-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Silveri, Jean M.
; REGISTRATION NUMBER: 39,030
; REFERENCE/DOCET NUMBER: UAG-004CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO. 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 845 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 20..845
; US-08-389-459A-3

```

```

Query Match 55.7%; Score 33.4; DB 1; Length 845;
Best Local Similarity 72.9%; Prod No. 0.019;
Matches 43; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Cy 1 GACATCAAGTGGTCTTCAAGAGAGCTTTGGGATATAGCTTCAATGTTCTTTCAAGAT 59
||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 482 GACATACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 59

```

```

RESULT 9
; Sequence 3, Application US/08987867A
; Patent No. 6063384
; GENERAL INFORMATION:
; APPLICANT: C. Morrow et al.
; TITLE OF INVENTION: ENCAPSIDATED RECOMBINANT VIRAL
; TITLE OF INVENTION: NUCLEIC ACID AND METHODS OF MAKING AND
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 24 STATE STREET
; CITY: BOSTON
; STATE: MASSACHUSETTS
; COUNTRY: USA
; ZIP: 02109
; COMPUTER FEASIBLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/987,867A
; FILING DATE: 09-DEC-1997
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/087,003
; FILING DATE: 01-JUL-1993
; ATTORNEY/AGENT INFORMATION:

```

```

; NAME: Myers, Louis
; REGISTRATION NUMBER 35,965
; REFERENCE/DOCET NUMBER: UAP-004CPDV
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 742-4214
; INFORMATION FOR SEQ ID NO. 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 845 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 20..845
; US-08-987-867A-3

```

```

Query Match 55.7%; Score 33.4; DB 3; Length 845;
Best Local Similarity 72.9%; Prod No. 0.019;
Matches 43; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Cy 1 GACATCAAGTGGTCTTCAAGAGAGCTTTGGGATATAGCTTCAATGTTCTTTCAAGAT 59
||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 482 GACATACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 59

```

```

RESULT 10
; 5204259-10
; Patent No. 5204259
; APPLICANT: HELTING, TORSTEN B., CREVIN, HAZAN, NURN,
; MICHAEL F.
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR PRODUCING HIV
; ANTIGENS
; NUMBER OF SEQUENCES: 20
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/344,237
; FILING DATE: 26-APR-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 191,299
; FILING DATE: 06-MAY-1988
; APPLICATION NUMBER: 191,229
; FILING DATE: 06-MAY-1988
; APPLICATION NUMBER: 206,499
; FILING DATE: 13-JUN-1988
; APPLICATION NUMBER: 258,016
; FILING DATE: 14-OCT-1988
; SEQ ID NO. 10:
; LENGTH: 871
; 5204259-10

```

```

Query Match 55.7%; Score 33.4; DB 6; Length 871;
Best Local Similarity 72.9%; Prod No. 0.019;
Matches 43; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Cy 1 GACATCAAGTGGTCTTCAAGAGAGCTTTGGGATATAGCTTCAATGTTCTTTCAAGAT 59
||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 472 GACATACAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 530

```

```

RESULT 11
; 5204259-8
; Patent No. 5204259
; APPLICANT: HELTING, TORSTEN B., CREVIN, HAZAN, NURN,
; MICHAEL F.
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR PRODUCING HIV
; ANTIGENS
; NUMBER OF SEQUENCES: 20
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/344,237
; FILING DATE: 26-APR-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 191,299

```


Search completed: February 4, 2003, 01:44:52
Job time : 9.52896 secs


```

; APPLICATION NUMBER: 191,229
; FILING DATE: 06-MAY-1988
; APPLICATION NUMBER: 206,499
; FILING DATE: 13-JUN-1988
; APPLICATION NUMBER: 258,016
; FILING DATE: 14-OCT-1988
; SEQ ID NO: 16
; LENGTH: 871
5204259-10

Query Match          55.7%; Score 33.4; DB 6; Length 871;
Best Local Similarity 72.9%; Pred. No. 0.023;
Matches 43; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1 GACATCGCCAGGCGCCCAAGAGAGCCCTTCGGGAACTAAGTGGAGAGTTCTTCAAGAC 59
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 472 GACATAGACAAAGGACCAAGAGAGAGCCCTTTAGAGACTATGTAGACCGGTCTATAAAG 530

RESULT 9
5204259-8
; Patent No. 5204259
; APPLICANT: HELMUT, TORSTEN B.; CPEVIN, HAKAN; NURN,
; MICHAEL F.
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR PRODUCING HIV
; ANTIGENS
; NUMBER OF SEQUENCES: 20
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/344,237
; FILING DATE: 26-APR-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 191,299
; FILING DATE: 06-MAY-1988
; APPLICATION NUMBER: 191,229
; FILING DATE: 06-MAY-1988
; APPLICATION NUMBER: 206,499
; FILING DATE: 13-JUN-1988
; APPLICATION NUMBER: 258,016
; FILING DATE: 14-OCT-1988
; SEQ ID NO: 8
; LENGTH: 1021
5204259-8

Query Match          55.7%; Score 33.4; DB 6; Length 1021;
Best Local Similarity 72.9%; Pred. No. 0.023;
Matches 43; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1 GACATCGCCAGGCGCCCAAGAGAGCCCTTCGGGAACTAAGTGGAGAGTTCTTCAAGAC 59
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 472 GACATAGACAAAGGACCAAGAGAGAGCCCTTTAGAGACTATGTAGACCGGTCTATAAAG 530

RESULT 10
US-08-463-210-5
; Sequence 5, Application US/08463210
; Patent No. 6001977
; GENERAL INFORMATION:
; APPLICANT: CHANG, Nancy T.
; APPLICANT: GALLO, Robert C.
; APPLICANT: WONG-STALL, Flossie
; TITLE OF INVENTION: CLONING AND EXPRESSION OF HTLV III DNA
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morgan & Finnegan, L.L.P.
; STREET: 345 Park Avenue
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10154-0853
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC DOS/MS-DOS

```

```

; SOFTWARE: Patent In Release #1 0, Version #1.25
; CURRENT APPLICATION DATA: US/08/463,210
; APPLICATION NUMBER: US/08/463,210
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 436
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 06/693,866
; FILING DATE: 23-JAN-1985
; PPIOP APPLICATION DATA:
; APPLICATION NUMBER: US 06/659,339
; FILING DATE: 10-OCT-1984
; ATTORNEY/AGENT INFORMATION:
; NAME: Serunian, Leslie A.
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 2026 4192US2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5362 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHEetical NO
; ORIGINAL SOURCE:
; ORGANISM: HTLV-III
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..5362
; OTHER INFORMATION: /standard name= "Clone BH5"
; OTHER INFORMATION: /note= "This sequence is a nucleotide position 222 to
; OTHER INFORMATION: 5585 in figure 3 of US 06/693,866 (parent)."
; US-08-463-210-5

Query Match          55.7%; Score 33.4; DB 3; Length 5362;
Best Local Similarity 72.9%; Pred. No. 0.026;
Matches 43; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1 GACATCGCCAGGCGCCCAAGAGAGCCCTTCGGGAACTAAGTGGAGAGTTCTTCAAGAC 59
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 960 GACATAGACAAAGGACCAAGAGAGAGCCCTTTAGAGACTATGTAGACCGGTCTATAAAG 1018

RESULT 11
US-08-850-049-128
; Sequence 128, Application US/88850049
; Patent No. 5965726
; GENERAL INFORMATION:
; APPLICANT:
; APPLICANT:
; APPLICANT:
; TITLE OF INVENTION: METHOD OF ELIMINATING
; TITLE OF INVENTION: INHIBITORY/INSTABILITY REGIONS OF mRNA
; NUMBER OF SEQUENCES: 130
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/850,049
; FILING DATE: 02-MAY-1997
; CLASSIFICATION: 435
; PPIOP APPLICATION DATA:

```


50 84 / 13A¹ATAA²7A¹AA³36¹A¹AAA¹37¹AA¹38¹TTTA¹39A¹3A¹ATAT¹40A¹41A¹42TTCTATAAAC 905

```

1  RESULT 9
2  US-09-943-722-128
3  Sequence 128, Application US/09943722
4  Publication No. US20020192660A1
5  GENERAL INFORMATION:
6  APPLICANT:
7  APPLICANT:
8  APPLICANT:
9  TITLE OF INVENTION: METHOD OF ELIMINATING
10 TITLE OF INVENTION: INHIBITORY/INSTABILITY REGIONS OF RNA
11 NUMBER OF SEQUENCES: 130
12 CORRESPONDENCE ADDRESS:
13 ADDRESSEE: MORGAN & FINNEGAN
14 STREET: 345 PARK AVENUE
15 CITY: NEW YORK
16 STATE: NEW YORK
17 COUNTRY: USA
18 ZIP: 10154
19 COMPUTER FEARDEFI FORM:
20 MEDIUM TYPE: FLOPPY DISK
21 COMPUTER: IBM PC COMPATIBLE
22 OPERATING SYSTEM: PC-DOS/MS-DOS
23 SOFTWARE: WORDPERFECT 5.1
24 CURRENT APPLICATION DATA:
25 APPLICATION NUMBER: US/09/943,722
26 FILING DATE:
27 CLASSIFICATION:
28 PRIOR APPLICATION DATA:
29 APPLICATION NUMBER: 08/850,049
30 FILING DATE:
31 PRIOR APPLICATION DATA:
32 APPLICATION NUMBER: US 08/050,478
33 FILING DATE: 26-OCT-1994
34 CLASSIFICATION:
35 PRIOR APPLICATION DATA:
36 APPLICATION NUMBER: PCT/US93/02408
37 FILING DATE: 29-MAR-1993
38 CLASSIFICATION:
39 PRIOR APPLICATION DATA:
40 APPLICATION NUMBER: US 07/858,747
41 FILING DATE: 27-MAR-1992
42 CLASSIFICATION:
43 ATTORNEY/AGENT INFORMATION:
44 NAME: MOREY, MARY J.
45 REGISTRATION NUMBER: 34,398
46 REFERENCE/DOCKET NUMBER: 2026-4006US1
47 TELECOMMUNICATION INFORMATION:
48 TELEPHONE: (212)758-4800
49 TELEFAX: (212)751-6849
50 INFORMATION FOR SEQ ID NO: 128:
51 SEQUENCE CHARACTERISTICS:
52 LENGTH: 7228 BASE PAIRS
53 TYPE: NUCLEIC ACID
54 STRANDEDNESS: SINGLE
55 TOPOLOGY: LINEAR
56 US-09-943-722-128
57
58 Query Match 55.78; Score 33.4; DB 9; Length 7229;
59 Best Local Similarity 72.98; Pred. No. 0.023, 16; Incls 0; Gaps 0;
60 Matches 43; Conservative 3; Mismatches 16;
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
9
```


Search completed: February 4, 2003, 01:44:59
Job time : 9 52896 secs

Db 2043 TTAAGCCAGCGGGGAAAGAAATATATAATTAATAATATAGTATGCGGCAAGCAGGGAG 2102
QY 121 CTGGAGAAAGTTCCGCTGAACCCCGGCTGCTGGAGACCGAGCGGCTGCAAGCAGATC 180
Db 2103 CTAGAAAGATTTGCGATTAATCTGGCTGTTAGAAACATTCAGAAAGCTCTAGACAAATA 2162
QY 181 ATCCGCGAGCTGCACCCCGCTGAGAGCCGAGCGAGAGCTGAAGAGCCTGTTCAAC 240
Db 2163 CTGGAGACAGCTACAAACCTGCTGAGACAGGATTCAGAAAGCTTATCATATATAT 2222
QY 241 ATGCTGCGACAGCTGATCTGCTGAGAGAGAGATCTGAGAGTCTGCGGAGATCAAAAGAGG 300
Db 2223 ACAGTAGAGAGAGTCTATCTGCTGATTAAGAGATATAGATAAAAGATATAGAGAGAGCT 2282
QY 301 CTGGAGAGAGATGAG 360
Db 2283 TTAGAGAGAGATGAG 2342
QY 361 GGC-----GAG 414
Db 2343 GAGACAG 2402
QY 415 CAGATGGTGCACAG 474
Db 2403 CAAATGGTACATCAG 2462
QY 475 GAG 534
Db 2463 GAG 2522
QY 535 CCGGAG 594
Db 2523 CCAG 598
QY 595 CTAAAG 654
Db 2583 TTAAAG 2642
QY 655 GAG 714
Db 2643 GAG 2702
QY 715 AG 774
Db 2703 AG 2762
QY 775 ATCTAG 834
Db 2763 ATTTATAAG 2822
QY 835 AGATAG 894
Db 2823 AGCATCTGAG 2882
QY 895 TTTAAAG 954
Db 2883 TATAAG 2942
QY 955 CTGAG 1014
Db 2943 CTGAG 3002
QY 1015 GTCAG 1074
Db 3003 GATAAG 3062
QY 1075 CTGAG 1128
Db 3063 AG 3122
QY 1129 AGCAAG 1188

Db 3123 GCGAATTTTAG 3182
QY 1159 ATGAG 1248
Db 3183 ACAG 3242
QY 1249 CAG 1308
Db 3243 CAG 3302
QY 1309 CAG 1368
Db 3303 TACAG 3362
QY 1369 GAG 1416
Db 3363 GAG 1422
QY 1417 AAG 1476
Db 3423 AAG 3482
QY 1477 TAA 1479
Db 3483 TAA 3485

RESULT 2
US-08-418-848A-9
; Sequence 9, Application US/08418848A
; Patent No. 5847096
; GENERAL INFORMATION:
; APPLICANT: SCHUBERT, MANFRED, HARMISON II,
; APPLICANT: GREGG G., CHANG-JIP, CHEN, PAMERIEA, AKHIL
; TITLE OF INVENTION: REPECTIVE, INTERPERING
; TITLE OF INVENTION: HIV PARTICLES
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESS: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 DASH AVENUE
; CITY: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORD PERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/418,848A
; FILING DATE: 07-APR-1995
; CLASSIFICATION: 526
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936,849
; FILING DATE: 28-AUG-1992
; CLASSIFICATION: 526
; ATTORNEY/AGENT INFORMATION:
; NAME: PICHARD W. BOK
; REGISTRATION NUMBER: 36,459
; REFERENCE/NOTICE NUMBER: 2036-4091US2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-758-4800
; TELEFAX: 212-751-6849
; TELEX: 421792
; INFORMATION FOR SEQ. ID NO. 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 799 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-418-848A-9

Query Match

43.6%; Score 645.4; DB 2; Length 7399;

; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA: US/08/488,551B
 ; APPLICATION NUMBER: US/08/488,551B
 ; FILING DATE: 07-JUN-1995
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PM3964 (AU)
 ; FILING DATE: 14-FEB-1994
 ; APPLICATION NUMBER: PM4002 (AU)
 ; FILING DATE: 21-FEB-1994
 ; APPLICATION NUMBER: PM0184 (AU)
 ; FILING DATE: 23-DEC-1994
 ; APPLICATION NUMBER: US 08/388,353
 ; FILING DATE: 14-FEB-1995
 ; APPLICATION NUMBER: PM3021/95
 ; FILING DATE: 17-MAY-1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: FRANK S. DIGILIO
 ; REFERENCE/DOC#ET NUMBER: 96062
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (516) 742-4343
 ; TELEFAX: (516) 742-4366
 ; INFORMATION FOR SEQ ID NO. 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 9709 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA
 ; US-08-488-551B-1

Query Match 43.6%; Score 645.4; DB 3; Length 9709;
 Best Local Similarity 66.4%; Pred. No. 1.4e-89;
 Matches 998; Conservative 0; Mismatches 481; Indels 24; Gaps 4;

QY 1 ATG393932393232CAGCATCTCTCTG39393232AAGTGTGACGCTCTG39393232CCTCCG 60
 Db 790 ATG393932393232CAGCATCTCTCTG39393232AAGTGTGACGCTCTG39393232CCTCCG 849
 QY 51 CTG393932393232CAGCATCTCTCTG39393232AAGTGTGACGCTCTG39393232CCTCCG 120
 Db 850 TTAAGGCCAGG39393232CAGCATCTCTCTG39393232AAGTGTGACGCTCTG39393232CCTCCG 909
 QY 121 CTGGAGAACTTCGCT 180
 Db 910 CTGAGAACTTCGCT 969
 QY 181 ATCCGCGAGCTG39393232CAGCATCTCTCTG39393232AAGTGTGACGCTCTG39393232CCTCCG 240
 Db 970 CTGGAGAACTTCGCT 1029
 QY 241 ACCGTGGCCACCT 300
 Db 1030 ACAATAGCAGTCT 1089
 QY 301 CTGGAGAACTTCGCT 360
 Db 1090 TTAGATAGATAGGAG 1149
 QY 361 GCC-----GACAAGGCGAGGTGAGCAGAACTACCCCATCTGTCAGAACTCTGTCAGAGCTTCAGGGC 414
 Db 1150 GACAAGGCGAGGTGAGCAGAACTACCCCATCTGTCAGAACTCTGTCAGAGCTTCAGGGC 1209
 QY 415 CAGATGCTGACAG 474
 Db 1210 CAAATGATACATCAGGCGCATATCCT 1269
 QY 475 GAGAGAGCTTCAGGCGCGAGGTGATCCCATCT 534
 Db 1270 GAGAGAGCTTCAGGCGCGAGGTGATCCCATCT 1329
 QY 535 CCAAG 594
 Db 1330 CCAAG 1389

QY 554 CTGAG 554
 Db 1390 TTAAG 1449
 QY 654 GGGGCGAG 714
 Db 1450 GGGGCGAG 1509
 QY 714 AGGAG 774
 Db 1510 AGGAG 1569
 QY 774 ATTCAG 834
 Db 1570 ATTCAG 1629
 QY 834 AGGAG 894
 Db 1630 AGGAG 1689
 QY 894 TTGAG 954
 Db 1690 TTGAG 1749
 QY 954 CTGCTGT 1014
 Db 1750 CTGCTGT 1069
 QY 1014 GCGAG 1074
 Db 1810 GCGAG 1869
 QY 1074 CGGAG 1128
 Db 1870 CGGAG 1929
 QY 1128 AGCAACTTCTCAAG 1188
 Db 1930 AGCAACTTCTCAAG 1989
 QY 1188 ATGCGCGAG 1248
 Db 1990 ATGCGCGAG 2049
 QY 1249 CACGAG 1308
 Db 2050 CACGAG 2109
 QY 1309 CACGAG 1368
 Db 2110 CACGAG 2169
 QY 1368 GAG 1416
 Db 2170 GAG 2229
 QY 1417 AAGGAG 1476
 Db 2230 AAGGAG 2289
 QY 1477 TAA 1479
 Db 2290 TAA 2292

RESULT 6
 US-09-309-572-15
 ; Sequence 15, Application US/09309572
 ; Patent No. 6440730
 ; GENERAL INFORMATION:
 ; APPLICANT: Heinrich-Pette-Institut
 ; TITLE OF INVENTION: Pettingbird light systems resoldered with LCMW

ATTORNEY/AGENT INFORMATION:
 NAME: COOPER, Iver P.
 REGISTRATION NUMBER: 28,005
 REFERENCE/DOCKET NUMBER: CHANG=112
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-628-5197
 TELEFAX: 202-737-3528
 INFORMATION FOR SEQ ID NO: 13:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12494 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 DESCRIPTION: /desc = "DNA"
 US-08-935-312-13

Query Match 43.6%; Score 645.4; DB 4; Length 12494;
 Best Local Similarity 66.4%; Pred. No. 1.4e-89;
 Matches 998; Conservative 0; Mismatches 481; Indels 24; Gaps 4;

QY 1 ATGGGGCGCCGCGCAGCATCTCGCGCGCGCAAGCTGGACGCGCTCGGAGCGGATCCGC 60
 Db 461 ATGGGTGCGAGAGCGCTCGGTATTAAAGCGGGGAGAAATTAGATAAATGGGAAAAAATTCGG 520

QY 61 CTGGCGCCCGCGCGCAAGGAGTGCTACATGATGAGCACTGCTGTGTCGCGCGCGCGAG 120
 Db 521 TTAAGGCCAGGGGGGAGAAACAATATAAATCTAAACATATAGTATGGGCAAGCAGGGAG 580

QY 121 CTGGAGAGCTTCGCCCTGAAACCCCGCGCTGCTGGAGACGACGAGCGCTGCAAGCAGATC 180
 Db 581 CTAGAAGCATTCGCAGTTTAATCTCGCCTTTTAGAGACATCAGAAGGCTGTAGACAAATA 640

QY 181 ATCCGCGCAGCTCACCGCGCTCGAGACCGCGCAGCGAGGAGCTGAGAGCGCTGTTCAAC 240
 Db 641 CTGGACAGCTCAACACCATCCCTTCAGACAGGATCAGAAGAAGCTTAGATCATTTATATAAT 700

QY 241 ACGGTGCGCAAGCTGTACTGTGTGCAAGAGATCGAGGTCGCGCGACACCAAGGAGGCG 300
 Db 701 ACAATAGCAGTCTCTATTGTGTGATCAAGGATAGATGTAAAGACACCAAGGAAGCC 760

QY 301 CTGGACAGATCGAGGAGGAGCAGCAAGCTGCGAGAGATGCGAGAGATCGAGCGCGGAGCG 360
 Db 761 TTAGATAAGATAGAGAGAGCAAGCAAAACAAAGTAAGAAAAAGGCACAGCAGCAGCT 820

QY 361 GCC-----GACAAGGGAGGTGAGCAGCACTACCCATCGTGCAGACCTGCGAGGCG 414
 Db 821 GACACAGGAAACCAAGCAGCGTCAAGCAAAATACCCATATAGTSCAGAACCTCCAGGGG 880

QY 415 CAGATGCTGTACAGGCGCATCAGCGCGCGCACTGTAAGCGCTGCGGAGGATCGAG 474
 Db 881 CAAATGCTACATCAGGCCATATCCTAGAACTTTAAATGCGATGGTAAAAGTAGTAGAA 940

QY 475 GAGAGCGCTTCAGCGCGCGAGGTGATGCGCGCATGTTTCACGCGCTGAGCGAGGCGCGACC 534
 Db 941 GAGAGCGCTTCAGCGCGCAAGTAATAATCCCATGTTTTCAGCATTTATCAGAAGGAGCGTCC 1000

QY 535 CCGCAGAGCTGAACACAGATGTGAACACCGTGGCGCGCGCGCGCGCGCGCGCGCGCGCG 594
 Db 1001 CTATATAATTTAAATACCATGCTTAAACATAGTGGGCGCGCGCGCGCGCGCGCGCGCG 1060

QY 595 CTGAAGACACCATCAACAGAGAGGCGCGCGCGAGTGGGCGCGCGCGCGCGCGCGCGCGCG 654
 Db 1061 TTAAGAGAGACCATCAATAGGAGAGTGAAGAAATTCAGAAATGAGATGATGATGATGATG 1120

QY 655 GCG 714
 Db 1121 GCG 774

QY 715 AGTACGCTGAGAGAGAGATGCTGTATGATGATGATGATGATGATGATGATGATGATGATG 774
 Db 1181 AGTACGCTTTCAGAGAAATAAGATGATGATGATGATGATGATGATGATGATGATGATG 1240

QY 775 ATCTACAAAGCGGTGGATCATCTTGGGCGCTCAACAAATATGCTGGGATGTACAGCGCGCG 834
 Db 1041 ATCTATAAAAGCATGATAATCTTGGGATTAATAAATAATGATAGAAATGATATAGCTATAC 1300

QY 835 AGCATCTGTGATCATCAAGTAAAGTGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 894
 Db 1301 AGCATCTGTGATCATCAAGTAAAGTGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1360

QY 895 TTAAGACCGCTGGCG 954
 Db 1361 TATAAAACTCTTAAGAGCG 1420

QY 955 CTGCTGTGCGCAGACGCGCAACCGCGAGCTGCAAGCATCTCTGCGCGCTCGCGCGCGCG 1014
 Db 1421 TTGTTGTGTCTAAATATGGAACCGCGAGATGTAAGACTATTTTAAAGACATTTGGGACCGA 1480

QY 1015 GCGACGCTAGAGAAATGATGACAGCATGTCAGGAGTGGGAGGAGGAGGAGGAGGAGGAG 1074
 Db 1481 GCGACACTAGAGAAATGATGACAGCATGTCAGGAGTGGGAGGAGGAGGAGGAGGAGGAG 1540

QY 1075 GCGGTGTGTGGCG 1128
 Db 1541 AGAGTTTTGGCTGAAGCGAATGAGCGCAAGTAAACAAATCCAGCTTACTATAATGATACAGA 1600

QY 1129 ACGAAATTAAGGCG 1188
 Db 1601 GCGAATTTTAGGAACTAAAGAAAGACTGTATAATGTTTCAATTTGTTTAAAGAGGCTAC 1660

QY 1189 ATCGAATGCGAACTAAAGTAAAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1248
 Db 1661 ATAGCAAAATTTGAGGCG 1720

QY 1249 CACGAGATCGAGGAGTGAAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1308
 Db 1721 CACCAATGGAAGAGATTACTGAGAGACAGGCTAAATTTTTAGGAGAGATTTGTTTTCG 1780

QY 1309 CACAAGGCG 1368
 Db 1781 CACAAGGCG 1840

QY 1369 GAGAGTTTGGCTTGGAGGGA-----GACATCTGCGCGCGCGCGCGCGCGCGCGCGCG 1416
 Db 1841 GAGAGTTTGGCTTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1500

QY 1417 AAGGACCGCGAGAGCTGACCGAGCTGTGAGAGCTGTGTTGTTGTTGTTGTTGTTGTTG 1476
 Db 1901 AAGGACGCTATCTCTTTAGCTTCTCAGATCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1960

QY 1477 TAA 1479
 Db 1961 TAA 1963

RESULT 8
 US-08-848-760B-33
 : Sequence 33, Application US/0848760B
 : Patent No. 6248721
 : GENERAL INFORMATION:
 : APPLICANT: Chang, Lung-Ji
 : TITLE OF INVENTION: Animal Model For Evaluation Of Vaccines
 : NUMBER OF SEQUENCES: 33
 : CORRESPONDENCE ADDRESS:
 : ADDRESSEE: Saliwanchik, Lloyd & Saliwanchik
 : STREET: 2401 N.W. 41st Street, Suite A-1
 : CITY: Gainesville
 : STATE: Florida
 : COUNTRY: United States of America
 : ZIP: 32606
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: PatentIn Release #1.0, Version #1.30

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

Db 958 GTCCAAATGCGAAGCCASATGTAAGACATATTTTASAGAGATTAGGACACAGGAGGATCA 1017
QY 1021 CTGGAGGAGATGATACCGCGCTGGCAGGCGCTGGGCGGCGGCGGCGGCGGCGGCGGCGG 1080
Db 1018 TTGAAGAGAAATGATGACAGCATGTCAAGGCGGTGGGAGGACCTGGGCGCAAAAGCAAGATTA 1077
QY 1081 CTGGCGGAGGCGATGAGCGAGCGCCACCA- --CCAGCGTGATGATGCGAGAGAGCAACTTC 1137
Db 1078 TTGGCTGGAGGCAATGAGTCAAAACAAACGATGGAACATATAATGATGCGAGAGAGCAATTTT 1137
QY 1138 AAGGCGCGCGCGCGCATCGTCAAGTGTCTTCAACTGCGGCGAAGGAGGCGCAATGCGGCGG 1197
Db 1138 AAGGCGCGCGCGCGCATGAGTGTCTTCAACTGCGGCGAAGGAGGCGCAATGCGGCGG 1197
QY 1198 AACTGCG 1257
Db 1198 AATTGCGAGAGCG 1257
QY 1258 AAGGATGCGAGAGCG 1317
Db 1258 AAGGATGCGAGAGCG 1317
QY 1318 CG 1377
Db 1318 AGGCGAGGGAATTCCTTCAGAACACAGACGAGCCACAGCGCGCGCGCGCGCGCGCGCG 1377
QY 1378 CGCTTCGAGGAGACACCG 1437
Db 1378 AGCTTCGAGGAGACACCG 1437
QY 1438 AGCTTCGAGGAGACACCG 1475
Db 1438 TCCTCAATCATCTCTTTGCGAGCGACCGCTGTGTCTCA 1475

RESULT 8
US-09-999-183-1
; Sequence 1, Application US/09999183
; Parent No. US20020147159A1
; GENERAL INFORMATION
; APPLICANT: MITROFANOV, et al
; TITLE OF INVENTION: In Vivo Selection Method
; FILE REFERENCE: 674523-2809
; CURRENT APPLICATION NUMBER: US/09/999,183
; PRIOR FILING DATE: 2001.11.29
; PRIOR APPLICATION NUMBER: PCT/GB00/02136
; PRIOR FILING DATE: 2000-06-02
; PRIOR APPLICATION NUMBER: 9912945.2
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: SeqWin99
; SEQ ID NO 1
; LENGTH: 4307
; TYPE: DNA
; GSEANISM: Human immunodeficiency virus type I
US-09-999-183-1

Query Match 44.0%; Score 650.2; DB 10; Length 4307;
Best Local Similarity 66.6%; Pred. No. 8,66-95;
Matches 1001; Conservative 0; Mismatches 478; Indels 24; Gaps 4;

QY 1 ATGCG 60
Db 1 ATGCG 60
QY 61 CTGCG 120
Db 61 TTAAGCG 120
QY 121 CTGCGAGAGGTTCCG 180
Db 121 CTAGAGCGATTCG 180

QY 191 ATCG 240
Db 191 CTGCG 240
QY 241 ACG 300
Db 241 ACG 300
QY 301 CTGCG 360
Db 301 TTAAGCG 360
QY 361 GCG 414
Db 361 GCG 414
QY 415 CAGCG 474
Db 421 CAGCG 480
QY 475 GAGCG 534
Db 481 GAGCG 540
QY 535 CCG 594
Db 541 CCG 600
QY 595 CTGCG 654
Db 601 TTAAGCG 660
QY 655 GCG 714
Db 661 GCG 720
QY 715 AGCG 774
Db 721 AGCG 780
QY 775 ATCG 834
Db 781 ATCG 840
QY 835 AGCG 894
Db 841 AGCG 900
QY 895 TTAAGCG 954
Db 901 TATAAGCG 960
QY 955 CTGCG 1014
Db 961 CTGCG 1020
QY 1015 GCG 1074
Db 1021 GCG 1080
QY 1075 CCG 1128
Db 1081 AGCG 1140
QY 1129 AGCG 1188
Db 1141 GCG 1200
QY 1189 ATCG 1248
Db 1201 ATCG 1260
QY 1249 CAGCG 1308


```
Db 452 CTGGACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATATAAT 511
QY 241 AAGCTGGACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 512 ACATAGACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 401 CTGATAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 572 TTACAGACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 361 GCG-----GACACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 632 GACACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 415 CAGATGGTACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 592 CAAATGGTACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 475 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 752 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 535 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 812 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 595 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 872 TTAAAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 655 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 942 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 715 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 932 AGTACAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 775 ATCTAAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1052 ATTTAAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 835 AGTACAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1112 AGTACAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 895 TTAAAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1172 TATAAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 965 CTGATAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1232 TTGTTGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 1015 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1292 GTTACAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 1095 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1352 AGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 1129 AGTACAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1412 GTTACAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 1189 ATGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1472 ACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 1245 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1532 CAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
```

```
QY 1309 CACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1592 TACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 1369 GAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1652 GAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 1417 AAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 1712 AAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
```

RESULT 14

```
US-09-943-286-3
: Sequence 3, Application US/09943286
: Patent No. US2002010668A1
: GENERAL INFORMATION:
: APPLICANT: Nunomura, Kiyotada
: TITLE OF INVENTION: POLYMER-LEVELLED AMPLIFICATION METHOD
: FILE REFERENCE: GP104-02 UT
: CURRENT AFFILIATION NUMBER: 93/001/43,286
: CURRENT FILING DATE: 2001-08-30
: NUMBER OF SEQ ID NOS: 9
: SOFTWARE: PasteSeq for Windows Version 3.0
: SEQ ID NO: 3
: LENGTH: 8933
: TYPE: PNA
: ORGANISM: Human Immunodeficiency Virus
: NAME/KEY: source
: LOCATION: (1) (8933)
: OTHER INFORMATION: Sequence of transcripts produced from the BH10
: OTHER INFORMATION: Plasmid.
US-09-943-286-3
```

```
Query Match 42.5%; Score 628; DB 10; Length 8933;
Best Local Similarity 52.9%; Prev No. 2.7e-91;
Matches 783; Conservative 141; Mismatches 440; Indels 12; Gaps 2;
```

```
QY 1 ATGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 113 ATGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 61 CTGATAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 173 UTAAAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 121 CTGATAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 233 CTGATAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 181 ATGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 293 CTGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 241 ATGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 353 ACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 301 CTGATAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 413 UTAAAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 361 GCC-----GACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 473 GACAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
QY 415 GAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
Db 533 CAGAGAGTAAATCATCTTTTACAGACAGGATACAGAAATTATATATAAT 511
```


1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing data, including digital databases and physical filing systems.

2. The second section focuses on the role of technology in modern record management. It highlights how software solutions can streamline processes, reduce errors, and improve accessibility. Examples of specific tools and platforms are provided, along with a discussion on the security measures necessary to protect sensitive information from unauthorized access or data breaches.

3. The third part of the document addresses the challenges associated with long-term data retention and archiving. It explores the legal requirements for preserving records and the potential risks of data loss or corruption over time. Recommendations are made for implementing robust backup strategies and for regularly reviewing and updating archival policies to ensure compliance with current regulations.

4. The final section discusses the importance of training and education for staff involved in record management. It stresses that while technology is a valuable asset, it is the knowledge and skills of the personnel that truly determine the effectiveness of the system. The text provides guidance on developing training programs, identifying key competencies, and fostering a culture of continuous learning within the organization.

US-09-353-362 7
; Sequence 7, Application US/09353362
; Patent No. 6383739
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Use of an "immunodeficiency-virus suppressing
; lymphokine (ISL)" to inhibit the replication of viruses,
; TITLE OF INVENTION: in particular of retroviruses
; NUMBER OF SEQUENCES: 8
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30B (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/353,362
; FILING DATE: 15-JUL-1999
; CLASSIFICATION:
; PRIORITY APPLICATION DATA
; APPLICATION NUMBER: DE 195 13 152.5
; FILING DATE: 07-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95113013.2
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: KLESNER, Sharon N.
; REGISTRATION NUMBER: 36,335
; REFERENCE/DOCYET NUMBER: P8341-9013
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-5000
; TELEFAX: (202) 638-4810
; TELEX:
; INFORMATION FOR SEQ ID NO. 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9737 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-353-362-7

[illegible]

Db 1311 ATAGCAAGAAATGCAAGGCCCTAGAAAAAGGGCTGTGTGGAAATGTGAAAGGAAGA 1370
QY 1249 CACCAAGATGAAGAGATGACACGAGGCGGAGGCAAACTTCTGCGGAAAGATGCTGGGCGGAGC 1308
Db 1371 CACCAAAATGAAAGATGTAAGTACAGAGAGAGAGGCTAATTTTATAGGGAAGATGCTGGGCTTC 1430
QY 1309 CACAAGGCG 1361
Db 1431 TACAAGGGAAGGCCCGGGAATTTCTTCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1490
QY 1362 CACG 1410
Db 1491 CTTTCAG 1550
QY 1411 ACCCG 1470
Db 1551 ACAACAACTCCCGCTCAGAAGCAGAGCGGATAGACAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1610
QY 1471 CTGGCGAGCGCTGTCGGGAGCG 1509
Db 1611 CTCAGATCACTCTTTGGCAAGACCGCCCTCGTCACAAATAA 1649

RESULT 13

US-09-124-900-1

; Sequence 1, Application US/09124900

; Patent No. 6268484

; GENERAL INFORMATION:

; APPLICANT: KATINSEP, Hermann

; APPLICANT: BUCHACHER, Andrea

; APPLICANT: EPNST, Wolfgang

; APPLICANT: BALLAUN, Claudia

; APPLICANT: PURTSCHER, Martin

; APPLICANT: TRKOLA, Alexandra

; APPLICANT: PREDL, Renate

; APPLICANT: SCHMALTZ, Christine

; APPLICANT: KLIMA, Annelies

; APPLICANT: STEINDL, Franz

; APPLICANT: MUSTER, Thomas

; TITLE OF INVENTION: HIV-Vaccines

; FILE REFERENCE: 1939-112P

; CURRENT APPLICATION NUMBER: US/09/124,900

; CURRENT FILING DATE: 1998-07-30

; PRIOR APPLICATION NUMBER: PCT/EP95/01481

; PRIOR FILING DATE: 1995-04-19

; NUMBER OF SEQ ID NOS: 11

; SOFTWARE: Patent in version 3.0

; SEQ ID NO 1

; LENGTH: 8932

; TYPE: DNA

; ORGANISM: Human immunodeficiency virus type 1

US-09-124-900-1

Query Match 41.8%; Score 631.4; DB 4; Length 8932;

Best Local Similarity 64.8%; Pred. No. 9.1e 89;

Matches 998; Conservative 0; Mismatches 511; Indels 30; Gaps 3;

QY 1 ATGGGTCG 60
Db 112 ATGGGTCGCGAGAGCGTCAGTATTAGCGGCGGAGAAATTAGATCGATGGGAAAAAATTCGG 171
QY 61 CTGGCGAG 120
Db 172 TTAAGCCAGGGGGAAGAAAAAATAAAATTTAAACATATAGTATGGCAAGCAGGGAG 231
QY 121 CTGGAGGCGCTTCTGCG 180
Db 232 CTAGAACGATTCGCGAGTTAATCTCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGAG 291
QY 181 ATGAACGAGTCTAGCG 240
Db 292 CTGGACACGCTACACG 351


```
QY 772 ATCTCAAGCGGTGGATCATCTCTGGGCTGACAGAGATCTGGGAGATGATACAGGCGCGGTG 831
Db 893 ATTATTAAAGATGGATAATCTCTGGGATTAAATATAATAGTAAGATGTATAGCGCTTACC 952
QY 832 AGCATCTTGGACATCGCGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 891
Db 953 AGTATTCTGGACATAAGACAAAGACAAAGACAAAGACAAAGACAAAGACAAAGACAAAGAC 1012
QY 892 TTCAAGACGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 951
Db 1013 TATAAAACCTCTAAGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1072
QY 952 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1031
Db 1073 TTGTTGGTCCAAATATGCGAAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1132
QY 1012 GTCACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1071
Db 1133 GCTACACTAGAGAAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1192
QY 1072 GCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1138
Db 1193 AGAGGTTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1252
QY 1129 AGCAACTTCAAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1188
Db 1253 GCGCAATTTTAGGAACTAAGAAAGATGGTTAAGTGTGTTTCAATTTGCGTAAAGAGGCG 1312
QY 1189 ATGCGCAAGAACTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1248
Db 1313 ACAGCCAGAGAAATGCGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1372
QY 1249 CACCGACATGAGGATGACCGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1308
Db 1373 CACCAATTAAGAAATTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1432
QY 1309 CACAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1361
Db 1433 TACAAGGAGAGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1492
QY 1362 -----TACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1410
Db 1493 CTTACAGAGCAGACACAGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1552
QY 1411 ACGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1470
Db 1553 ACNACAACTCCCGCTCAGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1612
QY 1471 CTGCGCAGCGCTGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1509
Db 1613 CTCAGATCACTCTTGGTAAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1651
```

RESULT 15

US-09-620-958A-3

Sequence 3, Application US/09620958A

Patent No. 6294338

GENERAL INFORMATION:

APPLICANT: Nunomura, Kiyotada

TITLE OF INVENTION: POLYNUCLEOTIDE AMPLIFICATION METHOD

FILE REFERENCE: GP104-02.07

CURRENT APPLICATION NUMBER: US/09-620-958A

CURRENT FILING DATE: 2000-07-21

NUMBER OF SEQ ID NOS: 9

SOFTWARE: FastSPQ for Windows Version 3.0

SEQ ID NO 3

LENGTH: 8933

TYPE: RNA

ORGANISM: Human Immunodeficiency Virus

FEATURE:

NAME/KEY: source

LOCATION: (1)---(8933)

OTHER INFORMATION: Sequence of transcripts produced from the BH10

; Patent No. 6294338
; OTHER INFORMATION: plasmid.

US-09-620-958A-3

Query Match

41.4%; Score 631.4; DB 4; Length 8933;

Best Local Similarity 55.2%; Pred. No. 9.1e-89;

Matches 849; Conservative 149; Mismatches 511; Indels 30; Gaps 3;

QY 1 ATGCG 60

Db 113 AUGGCG 172

QY 61 CTGCG 120

Db 173 TGAAGCG 232

QY 121 CTGCG 180

Db 233 TGAAGCG 292

QY 181 ATGCG 240

Db 293 TGAAGCG 352

QY 241 ACG 300

Db 353 TGAAGCG 412

QY 301 CTGCG 353

Db 413 TGAAGCG 472

QY 354 --CG 411

Db 473 TGAAGCG 532

QY 412 CAGCG 471

Db 533 TGAAGCG 592

QY 472 GAGCG 531

Db 593 TGAAGCG 652

QY 532 CCG 591

Db 653 TGAAGCG 712

QY 592 CTGCG 651

Db 713 TGAAGCG 772

QY 652 GCG 711

Db 773 GCG 832

QY 712 AGCG 771

Db 833 AGCG 892

QY 772 ATCTCAAGCGGTGGATCATCTCTGGGCTGACAGAGATCTGGGAGATGATACAGGCGCGGTG 831

Db 893 ATTATTAAAGATGGATAATCTCTGGGATTAAATATAATAGTAAGATGTATAGCGCTTACC 952

QY 832 AGCATCTTGGACATCGCGAGGCG 891

Db 953 AGTATTCTGGACATAAGACAAAGACAAAGACAAAGACAAAGACAAAGACAAAGACAAAGAC 1012

QY 892 TTCAAGACGCTGCG 951

Db 1013 TATAAAACCTCTAAGAGCG 1072

QY 952 CTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1031

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing data, including digital databases and physical filing systems. It also mentions the need for regular audits and reviews to ensure the integrity of the information.

2. The second part of the document focuses on the role of communication in achieving organizational goals. It highlights the importance of clear and concise communication, both internally and externally. The text provides guidelines for effective communication, such as using appropriate language, listening actively, and providing feedback. It also discusses the benefits of open communication and how it can foster a collaborative work environment.

3. The third part of the document addresses the issue of time management. It recognizes that time is a valuable resource and that efficient use of time is crucial for productivity. The text offers several strategies for managing time, including prioritizing tasks, setting deadlines, and delegating responsibilities. It also mentions the importance of taking breaks and avoiding procrastination to maintain focus and energy.

4. The fourth part of the document discusses the importance of continuous learning and development. It emphasizes that in a rapidly changing world, individuals and organizations must stay up-to-date with the latest knowledge and skills. The text outlines various ways to acquire new knowledge, such as attending workshops, taking courses, and seeking mentorship. It also mentions the importance of reflecting on one's own experiences and learning from mistakes.

5. The fifth part of the document discusses the importance of maintaining a positive attitude and mindset. It recognizes that a positive attitude can significantly impact one's performance and the overall success of an organization. The text provides several tips for maintaining a positive attitude, such as focusing on the positives, practicing gratitude, and staying motivated. It also mentions the importance of resilience and the ability to bounce back from setbacks.

6. The sixth part of the document discusses the importance of maintaining a healthy work-life balance. It recognizes that a healthy work-life balance is essential for long-term success and well-being. The text provides several strategies for achieving a healthy work-life balance, such as setting boundaries, prioritizing self-care, and seeking support. It also mentions the importance of taking regular breaks and avoiding burnout.

7. The seventh part of the document discusses the importance of maintaining a strong network of relationships. It recognizes that a strong network can provide valuable support and resources. The text provides several tips for building and maintaining a strong network, such as being proactive, offering help to others, and staying in touch. It also mentions the importance of being authentic and genuine in all interactions.

8. The eighth part of the document discusses the importance of maintaining a strong sense of purpose and mission. It recognizes that a strong sense of purpose can provide a clear direction and motivation. The text provides several tips for finding and maintaining a strong sense of purpose, such as reflecting on one's values, setting meaningful goals, and staying committed. It also mentions the importance of being inspired by others and the world around us.

9. The ninth part of the document discusses the importance of maintaining a strong sense of community and belonging. It recognizes that a strong sense of community can provide a sense of support and belonging. The text provides several tips for building and maintaining a strong sense of community, such as participating in group activities, offering help to others, and being inclusive. It also mentions the importance of being respectful and considerate of others.

10. The tenth part of the document discusses the importance of maintaining a strong sense of responsibility and accountability. It recognizes that a strong sense of responsibility is essential for success. The text provides several tips for maintaining a strong sense of responsibility, such as being honest, taking ownership of one's actions, and being reliable. It also mentions the importance of being transparent and open to feedback.